These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25505208)

  • 81. [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
    Lindner C; Dierneder J; Pall G; Pirich C; Hoffmann M; Raderer M; Becherer A; Niederle B; Lipp R; Lind P; Gallowitsch H; Romeder F; Virgolini I
    Nuklearmedizin; 2015; 54(3):125-30. PubMed ID: 25421138
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
    Waguespack SG; Sherman SI; Williams MD; Clayman GL; Herzog CE
    Thyroid; 2009 Apr; 19(4):407-12. PubMed ID: 19355831
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK; Gandhi S; George S
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [TBL] [Abstract][Full Text] [Related]  

  • 84. New Indication for Cabozantinib.
    Aschenbrenner DS
    Am J Nurs; 2022 Jan; 122(1):20-21. PubMed ID: 34941589
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Advanced thyroid cancers: new era of treatment.
    Mohammed AA; El-Shentenawy A
    Med Oncol; 2014 Jul; 31(7):49. PubMed ID: 24908065
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Multikinase inhibitors in thyroid cancer.
    Licitra L; Locati LD
    Ann Oncol; 2012 Sep; 23 Suppl 10():x328-33. PubMed ID: 22987985
    [No Abstract]   [Full Text] [Related]  

  • 87. Treatment of Aggressive Thyroid Cancer.
    Huang J; Harris EJ; Lorch JH
    Surg Pathol Clin; 2019 Dec; 12(4):943-950. PubMed ID: 31672300
    [TBL] [Abstract][Full Text] [Related]  

  • 88. FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
    Duke ES; Barone AK; Chatterjee S; Mishra-Kalyani PS; Shen YL; Isikwei E; Zhao H; Bi Y; Liu J; Rahman NA; Wearne E; Leighton JK; Stephenson M; Ojofeitimi I; Scepura B; Nair A; Pazdur R; Beaver JA; Singh H
    Clin Cancer Res; 2022 Oct; 28(19):4173-4177. PubMed ID: 35679021
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Response to sorafenib in a locally advanced oncocytic cell carcinoma of the thyroid.
    Pereira A; Parra D; Alvarez M; Rincon O
    BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38378588
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Development of molecular targeted drugs for advanced thyroid cancer in Japan.
    Takami H; Ito K; Sugino K
    Endocr J; 2014; 61(9):833-9. PubMed ID: 24849385
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature.
    Zago E; Galluzzo A; Pradella S; Antonuzzo L; Maggi M; Petrone L; Sparano C
    Endocrine; 2024 Jan; 83(1):26-40. PubMed ID: 37851242
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States.
    Dacosta Byfield SA; Adejoro O; Copher R; Chatterjee D; Joshi PR; Worden FP
    Adv Ther; 2019 Apr; 36(4):896-915. PubMed ID: 30820872
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tracheoesophageal fistula development following radiotherapy and tyrosine kinase inhibitors in a patient with advanced follicular thyroid carcinoma: a case-based review.
    S Temperley T; Temperley HC; O'Sullivan NJ; Corr A; Brennan I; Kelly ME; Prior L
    Ir J Med Sci; 2024 Jun; 193(3):1143-1147. PubMed ID: 37922099
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Gastropharyngeal Anastomotic Leak in Medullary Thyroid Carcinoma Following Initiation of a Tyrosine Kinase Inhibitor: A Case Report of an Unusual Side Effect of Cabozantinib.
    Ackerman J; Kent S; Walker P
    Ann Otol Rhinol Laryngol; 2020 Jul; 129(7):657-661. PubMed ID: 32037846
    [TBL] [Abstract][Full Text] [Related]  

  • 95. FDA Approved Uses of Cabozantinib.
    Leavitt J; Copur MS
    Oncology (Williston Park); 2019 Sep; 33(9):. PubMed ID: 31571185
    [No Abstract]   [Full Text] [Related]  

  • 96. Valuable insights from real-life experiences of advanced thyroid cancer treatment with sorafenib in Latin America.
    Farias EC; Hoff AO
    Arch Endocrinol Metab; 2021 Sep; 65(4):401-403. PubMed ID: 34525301
    [No Abstract]   [Full Text] [Related]  

  • 97. Proteinuria is a late-onset adverse event in patients treated with cabozantinib.
    Cappagli V; Moriconi D; Bonadio AG; Giannese D; La Manna G; Egidi MF; Comai G; Vischini G; Bottici V; Elisei R; Viola D
    J Endocrinol Invest; 2021 Jan; 44(1):95-103. PubMed ID: 32363491
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Sorafenib in thyroid cancer patients: learning from toxicity.
    Huillard O; Blanchet B; Boudou-Rouquette P; Thomas-Schoemann A; Wassermann J; Goldwasser F
    Oncologist; 2014 Aug; 19(8):e3. PubMed ID: 25052452
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Multikinase Inhibitor Treatment in Thyroid Cancer.
    Ancker OV; Krüger M; Wehland M; Infanger M; Grimm D
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31861373
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Drug approval: Cabozantinib monotherapy in advanced thyroid cancers refractory or not eligible for radioactive iodine treatment, after progression under previous systemic therapies].
    Matte P; Hadoux J
    Bull Cancer; 2022 Nov; 109(11):1103-1104. PubMed ID: 36220695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.